Remus Pharmaceuticals participates in the marketing and distribution of finished formulations of pharmaceutical drugs. Its business line can be classified into three major categories.
- API marketing and distribution
- Finished pharmaceutical drugs: marketing and distribution
- Technical consultancy to prepare reports on pharmaceutical dossiers
Remus Pharma distributes to generic distributors, and regional and multinational distributors to hospitals and clinics through a responsive distribution channel. It caters to clients spread across twenty countries.
As on January 31, 2023, Remus Pharma had a product portfolio of 429 products that it sells under different brand names in different countries.
Remus Pharmaceuticals Limited IPO Details
The IPO contains only fresh issues worth Rs. 47.69. In the book-building IPO, the price band is fixed at Rs. 1150-1229 per share. The bidding window will open on May 17, 2023, for retail investors.
Remus Pharmaceuticals Limited IPO Objective
The net proceeds from the fresh issues will be utilised in the areas below.
- Funding investment for an acquisition
- General corporate purposes and working capital requirements
- To meet the IPO expenses
Should you invest in Remus Pharmaceuticals Limited?
Here are a few key reasons to consider before investing in the IPO:
- The company offers a diversified product portfolio to its customers spread across 20 countries.
- Remus Pharma has a diversified business operation and revenue base.
- It is engaged with contract manufacturers that are WHO and GMP-compliant.
Competitive Peers
The other players in the segment recognised by the company are Trident Lifeline, Vaishali Pharma, and Chandra Bhagat Pharma Ltd.
Noteworthy Highlights of Remus Pharmaceuticals Limited
- The revenue from export has increased from Rs. 1,191.90 lakhs in FY 2020 to Rs. 2,316.23 lakhs in FY 2022.
IPO Financials
| Particulars | Period ending on December 31, 2022 | Year ending on March 31, 2022 |
|---|---|---|
| Revenue from Operations | 3,239.17 | 2,471.71 |
| Profit After Tax (PAT) | 643.90 | 338.57 |
| PAT Margin | 19.88% | 13.70% |
| EBITDA | 916.17 | 479.07 |
| EBITDA Margin | 28.28% | 19.38% |
| ROE | 54.68% | 71.44% |
Know before investing
Strengths
3It operates on a scalable business model.
The promoters are experienced in the pharmaceutical industry.
The company offers a wide product base of 429 products, with an additional 134 products in the process of registration in 16 countries.
Risks
3Dependency on suppliers and manufacturers can impact the company’s future business operations and financial performance.
The company lacks brand awareness.
The absence of steady cash flow and the non-availability of funds can impact the future performance and profitability of the business.
